In a commentary published in the New England Journal of Medicine yesterday, FDA outlined what it describes as its "new framework for psychedelic drugs". The four agency staffers kick off the article by outlining the severity of the mental health crisis in the U.S., focusing on depression and PTSD in particular, before stating that FDA […]
In a commentary published in the New England Journal of Medicine yesterday, FDA outlined what it describes as its "new framework for psychedelic drugs".
The four agency staffers kick off the article by outlining the severity of the mental health crisis in the U.S., focusing on depression and PTSD in particular, before stating that FDA […]
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
In a commentary published in the New England Journal of Medicine yesterday, FDA outlined what it describes as its "new framework for psychedelic drugs". The four agency staffers kick off the article by outlining the severity of the mental health crisis in the U.S., focusing on depression and PTSD in particular, before stating that FDA […]
Open the app view to save this story, compare related coverage, and continue from the same source.